SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee has joined Irth Capitals take-private effort are driving buyout speculation. Traders see the franchisees involvement as strengthening the bid, while others remain skeptical the board will accept a deal given its past decisions and the companys weak operating performance.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp XCN price spike, with traders citing a large candle and a sizable short-term gain but no clear news catalyst, is driving attention. The community is split between buying the dip and expecting a rebound, and warning that the recurring pumps quickly fade into sell-offs.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 DeLLphi-305 results for IMDELLTRA plus AstraZenecas IMFINZI in first-line small-cell lung cancer are driving attention, with traders highlighting the reported survival benefit and potential to expand IMDELLTRAs role. The community is weighing that pipeline opportunity against Repathas established sales growth as a key near-term business driver.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is drawing attention after a rally tied to the PHP2Shell web-server vulnerabilities, which prompted concern about widespread attacks and potential demand for Cloudflares WAF and traffic-protection services. Traders are framing the security scare as a possible business tailwind, while some focus on the sharp move and question whether it can continue.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is rallying with cybersecurity peers as AI-related security concerns and newly publicized vulnerabilities reinforce expectations for stronger enterprise security spending; traders also point to a bullish channel-partner survey suggesting budgets are firming. The move has drawn bullish momentum trading, while some investors question whether elevated valuations already reflect that demand.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

ESMO subgroup analyses from Celcuitys Phase 3 VIKTORIA-1 study are driving discussion, with traders highlighting favorable results for the gedatolisib triplet in PIK3CA-mutant breast cancer; the topline findings had been reported previously. Reactions are largely encouraged by the data, while some traders argue the stock still needs proof of commercial sales and execution, and the timing of an FDA label-expansion decision remains uncertain.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sonys plan to stop producing physical PlayStation game discs for new releases from 2028 is driving debate, with critics warning that losing resale and ownership options could push players away from PlayStation, while supporters argue a digital shift could improve margins. Traders are split on whether the move is a long-term business benefit or a risk to console demand and customer loyalty.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEOs sale of its Adelanto ICE facilities to DHS, followed by debt repayment and greater flexibility for share buybacks, dominates the discussion. Bulls see the transaction as strengthening the balance sheet and supporting shareholder returns, while others question why the stock weakened and worry about the implications of selling facilities for future operations.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs BNT113 cancer-immunotherapy trial missed its first primary endpoint of progression-free survival, though overall-survival analysis is ongoing. Traders are debating whether that setback and leadership concerns outweigh other oncology-pipeline signals, including pumitamig data; Modernas melanoma-vaccine success is also shaping comparisons between the companies.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs sharp selloff has traders debating its distributions sustainability and the companys financial outlook, including portfolio and hedging losses and debt concerns. Some blame short-selling or speculate about a cut, while bullish traders point to IEPs CVR Energy stake and hope for stronger cash returns; no single confirmed catalyst dominates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a...

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the...

Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development OfficerPR NewswireWALTHAM, Mass., Sept. 14...

Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Sept. 1, 2026 WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company...

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Aug. 5, 2026 -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical...

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Is Q32 Bio Stock Falling Wednesday?

Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the deal and share reaction.read more...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today? 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Citi raised Apple’s price target to $365 and expects stronger margins and continued market growth ahead of earnings.&nbsp;</li><li>Q32 Bio stock jumped 90% after positive Phase 2a trial results for bempikibart in severe alopecia areata.&nbsp;</li><li>CSX stock hit a record high of $49.90 after Raymond James raised its price target to $56 from $49.</li></ul>Apple Inc. (AAPL), Q32 Bio (QTTB) and CSX Corp. (CSX) each climbed to fresh 52-week highs on Monday as investors looked beyond broader market concerns and focused on earnings potential, clinical progress and improving industry conditions.&nbsp;Q32 Bio stock jumped 90%, while Apple and CSX stocks ended the session 0.6% and 0.4% higher, respectively.&nbsp;<h2 class="st-heading-2">Apple Hits Record High As Citi Raises Price Target Ahead Of Earnings&nbsp;</h2><a href="https://stocktwits.com/symbol/AAPL">Apple’s stock</a> reached a new all-time high of $323.45, extending its two straight weeks of gains after receiving renewed optimism from Wall Street analysts.Citi increased its target price on Apple shares to $365 from $315 while reiterating its ‘Buy’ rating. The firm believes Apple is in a strong position ahead of its fiscal Q3 earnings and can continue growing its market share even as overall device sales slow.&nbsp;According to Citi, the higher price target reflects improved margin expectations following Apple's recent product price increases.&nbsp;Despite the smartphone industry slowdown, Apple saw its smartphone&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-s-i-phone-and-google-pixel-q2-sales-shine-even-as-global-smartphone-market-drops-to-13-year-low/cZmCbU0R7Yp">shipments</a> rise 3% year-on-year in Q2, according to&nbsp;Counterpoint Research. Apple captured a record 20% share of the global market in the quarter, helped by strong demand for its iPhone 17 lineup.&nbsp;On Stocktwits, retail sentiment around the stock turned to ‘neutral’ from ‘bearish’ the previous day.&nbsp;<h2 class="st-heading-2">Q32 Bio Surges After Promising Hair Loss Drug Trial Results&nbsp;</h2><a href="https://stocktwits.com/symbol/QTTB">Q32 Bio stock</a> delivered the session's biggest move, hitting a 19-month high of $22.50 after reporting encouraging Phase 2a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qttb-stock-clocks-best-day-in-a-year-following-positive-alopecia-data-analyst-sees-further-200-upside/cZmCTpsR7Yq">data</a> for bempikibart in patients with severe alopecia areata (hair fall). The experimental anti-IL-7Rα therapy produced meaningful improvements in hair regrowth, including a 40% SALT-20 (a standard tool for measuring alopecia severity) response after 36 weeks.&nbsp;The company also outlined plans to pursue a registration-directed development program by the first half of 2027 and announced a $200 million public stock offering to help finance future clinical development.After the data, Wells Fargo analyst Derek Archila upgraded Q32 Bio to ‘Overweight’ from ‘Equal Weight’ and raised the price target sharply from $10 to $66. The firm said the trial results increased its confidence that bempikibart could succeed as a treatment.The firm also believes Q32 Bio could grow significantly, potentially reaching a market value of about $2 billion after the company strengthens its financial position. Retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;<h2 class="st-heading-2">CSX Hits Record High As Raymond James Raises Price Target&nbsp;</h2><a href="https://stocktwits.com/symbol/CSX">CSX stock</a> reached a record high of $49.90 after Raymond James raised its price target on CSX to $56 from $49 and maintained an ‘Outperform’ rating.The firm expects the transportation company to report stronger fiscal second-quarter (Q2) results, citing operational improvements and a better setup in the freight market.According to Raymond James, the transportation sector is benefiting from tighter supply conditions even though overall demand remains relatively soft. The firm believes this imbalance could create a more favorable environment for rail operators as industry conditions continue to stabilize.However, retail sentiment toward the stock turned from ‘bearish’ to ‘neutral’ in a day.So far this year, AAPL and CSX stocks have gained 16% and 36%, respectively, while QTTB stock has surged 543%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dis-stock-gains-nearly-2-why-wells-fargo-says-disney-could-jump-40-if-it-exits-streaming/cZmzwRyR7Y0">DIS Stock Gains Nearly 2% — Why Wells Fargo Says Disney Could Jump 40% If It Exits Streaming</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Apple logo appears on the screen of a smartphone placed on a surface reflecting the new Siri logo.

Apple Inc. (AAPL), Q32 Bio (QTTB) and CSX Corp. (CSX) each climbed to fresh 52-week highs on Monday as investors looked beyond broader market concerns and focused on earnings potential, clinical progress and improving industry conditions.&nbsp;

Investors backed strong catalysts, including analyst upgrades, biotech trial results and improving freight outlooks. 


Apple Inc

CSX Corp.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$QTTB $33 million enterprise value basically doesn’t see worth from bempikibart. Leerink estimates $1.8 billion peak yearly sales

JeremyDanie

$QTTB self fulfilling prophecy on steroid. Investors are afraid to hold because it might drop so they sell and that’s why it keeps dropping. Some circular nightmare.

Jack S

$QTTB strange how a derisked potential first line asset can be trading at these levels 🤔 at the very least this has to attract M&A intrest

Blake Lundgren

$QTTB SeekingAlpha ratings don't get much better than this. Definitely a STRONG BUY at these levels

Feed

News

Sentiment

Earnings

Fundamentals

Info

QTTB Q32 Bio Inc.

Fundamentals

Latest QTTB News